Search Results - "Vahanian, Nicholas N."

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan by Metz, Richard, Rust, Sonja, DuHadaway, James B., Mautino, Mario R., Munn, David H., Vahanian, Nicholas N., Link, Charles J., Prendergast, George C.

“…Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO) alters inflammation and favors T-cell tolerance in cancer, but the underlying molecular mechanisms…”
Get full text

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors by Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N, Jay Ramsey, W, Kennedy, Eugene, Mautino, Mario R, Link, Charles J, Lin, Ray S, Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M, Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H, Janik, John E, Khleif, Samir N

“…Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance…”
Get full text

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma by Zakharia, Yousef, McWilliams, Robert R, Rixe, Olivier, Drabick, Joseph, Shaheen, Montaser F, Grossmann, Kenneth F, Kolhe, Ravindra, Pacholczyk, Rafal, Sadek, Ramses, Tennant, Lucinda L, Smith, Christopher M, Kennedy, Eugene P, Link Jr, Charles J, Vahanian, Nicholas N, Yu, Jiayi, Shen, Steven S, Brincks, Erik L, Rossi, Gabriela R, Munn, David, Milhem, Mohammed

“…BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor…”
Get full text

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses by Chen, Wenlan Alex, Zhang, Jinjin, Hall, Katie M, Martin, Carol B, Kisselev, Serguei, Dasen, Emily J, Vahanian, Nicholas N, Link, Charles J, Martin, Brian K

“…Highly pathogenic avian influenza represents a severe public health threat. Over the last decade, the demand for highly efficacious vaccines against avian…”
Get full text

Pancreatic cancer: Update on immunotherapies and algenpantucel-L by McCormick, Kinsey A., Coveler, Andrew L., Rossi, Gabriela R., Vahanian, Nicholas N., Link, Charles, Chiorean, E. Gabriela

“…Pancreatic adenocarcinoma is notoriously lethal, and despite improvements in systemic chemotherapy approaches bringing survival rates for metastatic disease to…”
Get full text

Hematopoietic Mixed Chimerism Derived from Allogeneic Embryonic Stem Cells Prevents Autoimmune Diabetes Mellitus in NOD Mice by Verda, Larissa, Kim, Duck An, Ikehara, Susumu, Statkute, Laisvyde, Bronesky, Delphine, Petrenko, Yevgeniya, Oyama, Yu, He, Xiang, Link, Charles, Vahanian, Nicholas N., Burt, Richard K.

“…Embryonic stem cell (ESC)‐derived hematopoietic stem cells (HSC), unlike HSC harvested from the blood or marrow, are not contaminated by lymphocytes. We…”
Get full text

A phase I study of indoximod in patients with advanced malignancies by Soliman, Hatem H, Minton, Susan E, Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A, Roberts, John D, Link, Charles, Vahanian, Nicholas N, Mautino, Mario, Streicher, Howard, Sullivan, Daniel M, Antonia, Scott J

“…Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum…”
Get full text

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors by Soliman, Hatem H, Jackson, Erica, Neuger, Tony, Dees, E Claire, Harvey, R Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N, Link, Charles, Sullivan, Daniel M, Antonia, Scott

“…Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical…”
Get full text

Algenpantucel-L immunotherapy in pancreatic adenocarcinoma by Coveler, Andrew L, Rossi, Gabriela R, Vahanian, Nicholas N, Link, Charles, Chiorean, E Gabriela

“…Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with surgically resectable and…”
Get full text

A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge by Mandell, Robert B, Koukuntla, Ramesh, Mogler, Laura J.K, Carzoli, Andrea K, Freiberg, Alexander N, Holbrook, Michael R, Martin, Brian K, Staplin, William R, Vahanian, Nicholas N, Link, Charles J, Flick, Ramon

“…Abstract Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are…”
Get full text

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens by Hemstreet, 3rd, George P, Rossi, Gabriela R, Pisarev, Vladimir M, Enke, Charles A, Helfner, Laura, Hauke, Ralph J, Tennant, Lucinda, Ramsey, William Jay, Vahanian, Nicholas N, Link, Charles J

“…The immunogenicity of a cellular immunotherapy using genetically modified vaccines to express α(1,3)galactosyl epitopes (αGal) was evaluated in advanced…”
Get full text

Combination immunotherapy for high-risk resected and metastatic melanoma patients by Riker, Adam I, Rossi, Gabriela R, Masih, Prerna, Alsfeld, L C, Denham, Fiona, Tennant, Lucinda, Ramsey, W Jay, Vahanian, Nicholas N, Link, Charles J

“…Patients with advanced melanoma have a poor outcome. We hypothesize that combination immunotherapy can synergistically activate host immunity to generate an…”
Get full text

Herpes simplex amplicon vectors by Link, Charles J, Vahanian, Nicholas N, Wang, Suming

Get more information

Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC) by Hahn, Andrew W, Drake, Charles G., Denmeade, Samuel R., Zakharia, Yousef, Maughan, Benjamin Louis, Kennedy, Eugene Paul, Link, Charles J., Vahanian, Nicholas N., Hammers, Hans J., Agarwal, Neeraj

“…Abstract only 590 Background: HyperAcute Renal (HAR) immunotherapy consists of two allogeneic renal cancer cell lines that have been genetically modified to…”
Get full text

A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer by Hammers, Hans J., Drake, Charles G., Zakharia, Yousef, Kennedy, Eugene Paul, Vahanian, Nicholas N., Link, Charles J., Agarwal, Neeraj

“…Abstract only 528 Background: HyperAcute Renal (HAR) immunotherapy consists of two allogeneic renal cancer cell lines that have been genetically modified to…”
Get full text

Addition of [alpha]Gal HyperAcute[TM] technology to recombinant avian influenza vaccines induces strong low-dose antibody responses by Chen, Wenlan Alex, Zhang, Jinjin, Hall, Katie M, Martin, Carol B, Kisselev, Serguei, Dasen, Emily J, Vahanian, Nicholas N, Link, Charles J, Martin, Brian K

“…Highly pathogenic avian influenza represents a severe public health threat. Over the last decade, the demand for highly efficacious vaccines against avian…”
Get full text

Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer by Bahary, Nathan, Garrido-Laguna, Ignacio, Wang-Gillam, Andrea, Nyak-Kapoor, Asha, Kennedy, Eugene, Vahanian, Nicholas N., Link, Charles J.

“…Abstract only 452 Background: IDO is a tryptophan-catabolizing enzyme that plays a key role in the normal regulation of peripheral immune tolerance. Tumors…”
Get full text

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer by Bahary, Nathan, Wang-Gillam, Andrea, Haraldsdottir, Sigurdis, Somer, Bradley G., Lee, Jin S., O'Rourke, Mark Allen, Nayak-Kapoor, Asha, Beatty, Gregory Lawrence, Liu, Mingen, Delman, Devora, Rossi, Gabriela R., Kennedy, Eugene Paul, Vahanian, Nicholas N., Link, Charles J., Garrido-Laguna, Ignacio

“…Abstract only…”
Get full text

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma by Zakharia, Yousef, Rixe, Olivier, Ward, John Harris, Drabick, Joseph J., Shaheen, Montaser F., Milhem, Mohammed M., Munn, David, Kennedy, Eugene Paul, Vahanian, Nicholas N., Link, Charles J., McWilliams, Robert R.

“…Abstract only…”
Get full text

Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma by Kennedy, Eugene, Rossi, Gabriela R., Vahanian, Nicholas N., Link, Charles J.

“…Abstract only…”
Get full text